Yeji

Upcoming catalysts

PDUFA target dates, FDA Advisory Committees, Phase 3 readouts, and approvals surfacing in the next 180 days.

All catalystsPDUFAAdComsReadoutsFDA decisions
30d90d180d365d

July 2026 · 1

PDUFAJul 11, 2026· in 35d
$CORTCORCEPT THERAPEUTICS INC
relacorilant · hypertension secondary to hypercortisolism
“The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026 for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.”

August 2026 · 1

PDUFAAug 23, 2026· in 78d
$RAREUltragenyx Pharmaceutical Inc.
pariglasgene brecaparvovec · Glycogen Storage Disease Type Ia (GSDIa)
“The FDA granted the BLA Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) action date of August 23, 2026.”

September 2026 · 2

PDUFASep 19, 2026· in 105d
$RAREUltragenyx Pharmaceutical Inc.
ux111 · Sanfilippo syndrome Type A (MPS IIIA)
“The FDA set a Prescription Drug User Fee Act (PDUFA) action date of September 19, 2026.”
PDUFASep 22, 2026· in 108d
$IONSIONIS PHARMACEUTICALS INC
zilganersen · Alexander disease (AxD)
“Zilganersen is currently under Priority Review by the U.S. Food and Drug Administration with a Prescription Drug User Fee Act action date of September 22, 2026.”